$2.2 Billion J&J/Risperdal Settlement: Only The Beginning

via Mad in America;
$2.2 Billion Settlement: Only The Beginning

November 15, 2013

At least 250 lawsuits involving Johnson & Johnson’s improper marketing of Risperdal are pending in Pennsylvania’s Philadelphia Court of Common Pleas, according to information provided by a law firm involved in the litigation.  The firm, which represents individuals who may have developed gynecomastia (male breast growth) as a result of the drug, alleges that the unapproved use of Risperdal to treat ADHD is also on the rise.

Press Release→

Further reading:Antipsychotic Risperdal Slapped with $2 Billion Dementia Penalty (Alzheimer’s & Dementia Weekly)

This entry was posted in Antipsychotics, Featured News, In the News, Industry, Psychiatric Drugs,Uncategorized by Kermit Cole. Bookmark the permalink.

Thank You Mr Cole, and MIA.

Read more:

State AGs (15)

pic cred to MIA